October Effect’s CorMedix CRMD Stock Holding History

October Effect’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-306,444	Closed	-$3.56M	–	68
2025 Q4	$3.56M	Sell	306,444 -114,107	-27%	-$1.26M	3.93%	5
2025 Q3	$4.89M	Buy	420,551 +111,794	+36%	+$1.35M	5.39%	4
2025 Q2	$3.8M	Buy	+308,757	New	+$3.41M	4.59%	7

Other funds holding CRMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

October Effect's CRMD Position: Q1 2026 in Review

October Effect sold out of CorMedix (CRMD) in Q1 2026, closing a stake of 306,444 shares — an estimated $3.56M sold.

October Effect first reported a position in CRMD in Q2 2025 and held it in 3 quarters. The position peaked at $4.89M in Q3 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

October Effect reported no remaining CorMedix position as of Q1 2026 after selling out during the quarter.
October Effect sold 306,444 CorMedix shares in Q1 2026, an estimated $3.56M.
October Effect first reported a position in CorMedix in Q2 2025 and held it in 3 quarters.
October Effect's CorMedix position peaked at $4.89M in Q3 2025.
187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on October Effect's 13F filing for Q1 2026, filed 21 Apr 2026.